Gongwin Biopharm Holdings Co (ROCO:6617) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Gongwin Biopharm Holdings Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gongwin Biopharm Holdings Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Gongwin Biopharm Holdings Co's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.00). It may suggest that Gongwin Biopharm Holdings Co is progressively becoming more dependent on debt to grow their business.

Gongwin Biopharm Holdings Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Gongwin Biopharm Holdings Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gongwin Biopharm Holdings Co LT-Debt-to-Total-Asset Chart

Gongwin Biopharm Holdings Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Gongwin Biopharm Holdings Co Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Gongwin Biopharm Holdings Co LT-Debt-to-Total-Asset Calculation

Gongwin Biopharm Holdings Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.029	/	1515.348
	=	0.00

Gongwin Biopharm Holdings Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	13.238	/	3453.699
	=	0.00

Gongwin Biopharm Holdings Co (ROCO:6617) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Gongwin Biopharm Holdings Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Gongwin Biopharm Holdings Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Gongwin Biopharm Holdings Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491

Website

http://www.gongwinbiopharm.com

Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.

Gongwin Biopharm Holdings Co Headlines

No Headlines